CLASS II Drug recall · Reported 6 Feb 2019 · FDA Enforcement Report

Fexofenadine HCl Tablets, USP, 180 mg recalled by Mylan Pharmaceuticals

Mylan Pharmaceuticals is recalling Fexofenadine HCl Tablets, USP, 180 mg, distributed nationwide in the US. The recall was initiated on 18 Jan 2019 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: a) 3085490, 3085491, Exp 04/19; b) 3085492, 3085493, 3085494, 3085495, 3085496, Exp 04/19
Quantity recalled88,090 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0428-2019
FDA event ID
81930
Recalling firm
Mylan Pharmaceuticals, Morgantown, WV
Classification
Class II
Status
Terminated
Recall initiated
18 Jan 2019
FDA classified
4 Feb 2019
Reported
6 Feb 2019
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

18 Jan 2019Recall initiated by company
4 Feb 2019Classified by FDA+17 days
6 Feb 2019Published in enforcement report+2 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Impurities/Degradation Specifications: Related compound results obtained during routine stability testing was slightly elevated above specification.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Fexofenadine HCl Tablets, USP, 180 mg, packaged in a) 30-count bottles (NDC 0378-0782-93) and b) 500-count bottles (NDC 0378-0782-05); Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA.

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Is Fexofenadine HCl Tablets, USP, 180 mg recalled?

Yes. Mylan Pharmaceuticals recalled Fexofenadine HCl Tablets, USP, 180 mg on 18 Jan 2019. The recall is Class II and its status is Terminated. Recall number D-0428-2019.

Why was it recalled?

Failed Impurities/Degradation Specifications: Related compound results obtained during routine stability testing was slightly elevated above specification.

Which lots are affected?

Lot #: a) 3085490, 3085491, Exp 04/19; b) 3085492, 3085493, 3085494, 3085495, 3085496, Exp 04/19

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Mylan Pharmaceuticals

All 84

Other Fexofenadine recalls

All 24